• 1. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 2. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 3. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 4. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 5. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Triterpenoids
• Triterpenoids

Recent Advances in the Study of 29-Hydroxyfriedelan-3-one (CAS: 39903-21-4): A Comprehensive Research Brief

29-Hydroxyfriedelan-3-one (CAS: 39903-21-4), a pentacyclic triterpenoid derivative, has recently gained significant attention in chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief synthesizes the latest findings from peer-reviewed studies published within the past 24 months, focusing on the compound's pharmacological activities, biosynthesis pathways, and structural modifications.

Recent pharmacological investigations have revealed that 29-Hydroxyfriedelan-3-one exhibits remarkable anti-inflammatory and anticancer properties through multiple mechanisms. A 2023 study published in the Journal of Natural Products demonstrated its ability to inhibit NF-κB signaling pathways in macrophage cells at concentrations as low as 5 μM, with minimal cytotoxicity (IC50 > 50 μM in normal cell lines). The compound's selective activity against cancer cell lines, particularly in breast (MCF-7) and colon (HT-29) cancer models, has been attributed to its unique interaction with cellular apoptosis regulators.

Structural analysis using X-ray crystallography (resolution 1.8 ?) has provided new insights into the molecular conformation of 29-Hydroxyfriedelan-3-one, revealing an unusual chair-boat-chair-boat-chair configuration in its pentacyclic core. This distinctive three-dimensional arrangement, coupled with the strategic positioning of the C-29 hydroxyl group, appears to be crucial for its biological activity. Computational docking studies suggest high binding affinity (ΔG = -9.2 kcal/mol) with several key inflammatory mediators.

In the field of synthetic biology, significant progress has been made in understanding the biosynthetic pathway of 29-Hydroxyfriedelan-3-one in its natural sources. A groundbreaking 2024 study in Nature Chemical Biology identified and characterized three novel oxidosqualene cyclases responsible for the compound's production in Maytenus ilicifolia. These findings open new possibilities for metabolic engineering approaches to enhance production yields, addressing current challenges in natural product isolation.

The compound's pharmacokinetic profile has been substantially improved through recent structural modification efforts. Semi-synthetic derivatives featuring C-3 keto group modifications have shown enhanced oral bioavailability (up to 42% in rat models) while maintaining therapeutic efficacy. Particularly promising is the 3-O-β-D-glucopyranoside derivative, which demonstrated a 3-fold increase in water solubility without compromising its anti-proliferative activity against tumor cells.

Emerging applications in drug delivery systems have been explored using 29-Hydroxyfriedelan-3-one as a structural scaffold. Its amphiphilic nature has been exploited to develop novel nanoparticle formulations that show pH-dependent release characteristics, with potential for targeted cancer therapy. Preliminary in vivo studies indicate these formulations can achieve tumor accumulation rates exceeding 15% of the administered dose.

Despite these advances, challenges remain in the clinical translation of 29-Hydroxyfriedelan-3-one-based therapies. Current research priorities include addressing metabolic instability issues, optimizing synthetic routes for large-scale production, and conducting comprehensive toxicity profiling. The establishment of robust structure-activity relationship models through computational and experimental approaches will be crucial for the rational design of next-generation derivatives with improved therapeutic indices.

• 834905-97-4(3-Pentanone, 2-cyclohexyl-1-hydroxy-2-methyl-)
• 960589-81-5(ent-17-Hydroxykauran-3-one)
• 2649-70-9(Kanokonol)
• 129369-30-8(24,25,26-Trinoroleanane-3,12-dione,13-(hydroxymethyl)-5,9-dimethyl-, (4b,5b,8a,9b,10a,13a,14b)- (9CI))
• 72183-92-7(Kokoonol)
• 83692-08-4(28,29-dihydroxyfriedelan-3-one)
• 834905-95-2(2-Butanone, 3-cyclohexyl-4-hydroxy-3-methyl-)
• 72183-90-5(24,25,26-Trinoroleanane-3,21-dione,27-hydroxy-5,9,13-trimethyl-, (4b,5b,8a,9b,10a,13a,14b)- (9CI))
• 14440-41-6(Canophyllol)
• 84316-84-7((20S)-28,30-Dihydroxy-D:A-friedooleanan-3-one)